BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Radunz S, Treckmann J, Baba HA, Best J, Müller S, Theysohn JM, Paul A, Benkö T. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment. Ann Transplant 2017;22:215-21. [PMID: 28408731 DOI: 10.12659/aot.902595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Yu Z, Li H, Yi S, Liu W, Yang Y, Wang G. Severe bile duct complication after yttrium-90 radioembolization therapy in a patient with recurrent hepatocellular carcinoma after liver transplantation: A case report. Liver Research 2021;5:33-5. [DOI: 10.1016/j.livres.2020.10.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Levi Sandri GB, Ettorre GM, Giannelli V, Colasanti M, Sciuto R, Pizzi G, Cianni R, D'Offizi G, Antonini M, Vennarecci G, Lucatelli P. Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. Transl Gastroenterol Hepatol 2017;2:98. [PMID: 29264436 DOI: 10.21037/tgh.2017.11.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
3 Bauschke A, Altendorf-Hofmann A, Ardelt M, Kissler H, Tautenhahn HM, Settmacher U. Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis. J Cancer Res Clin Oncol 2020;146:1819-27. [PMID: 32356179 DOI: 10.1007/s00432-020-03215-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Mikell JK, Dewaraja YK, Owen D. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semin Radiat Oncol 2020;30:68-76. [PMID: 31727302 DOI: 10.1016/j.semradonc.2019.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
5 Öcal O, Ingrisch M, Ümütlü MR, Peynircioglu B, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Iezzi R, Benito A, Pech M, Malfertheiner P, Ricke J, Seidensticker M. Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma. Br J Cancer 2021. [PMID: 34686780 DOI: 10.1038/s41416-021-01577-6] [Reference Citation Analysis]
6 Soresi M, Licata A, Giannitrapani L, Montalto G. Waiting-time and quality of care deserved to patients with early stage hepatocellular carcinoma undergoing RFA treatment. Ann Hepatol 2017;16:699-701. [PMID: 28809739 DOI: 10.5604/01.3001.0010.2706] [Reference Citation Analysis]